This is an industry funded study led by Dr. Kim Huffman and sponsored by Flexion Therapeutics, Inc. The primary objective of this study is to assess the effect of a single intra-articular (IA) injection of FX006 32 mg to control inflammation as measured by a reduction in MRI-assessed synovial volume in patients with symptomatic osteoarthritis (OA) of the knee. The study will enroll up to 40 participants. Each subject will be active in the study for up to 28 weeks. All study visits and procedures will be performed at the Duke Center for Living campus and the Duke Center for Advanced Magnetic Resonance Development (CAMRD) imaging lab at Duke Medical Center.

Download our flyer.